Results 241 to 250 of about 264,257 (370)

The BH3‐only protein NOXA is essential for apoptosis induction by BH3‐mimetics targeting BCL2 or BCL‐XL in DLBCL

British Journal of Haematology, EarlyView.
Summary BCL2 inhibitors (BCL2i) have transformed the management of chronic lymphocytic leukaemia (CLL), but their use in more aggressive B‐cell malignancies such as diffuse large B‐Cell lymphoma (DLBCL) is complicated by the more heterogeneous nature of the disease.
Nahide Yildirim, Marius Anders, Victoria M. Smith, Sandrine Jayne, Moritz Assmann, Rebekah Jukes‐Jones, Martin J. S. Dyer, Meike Vogler   +7 more
wiley   +1 more source

Diffuse Large B Cell Lymphoma presenting as Right Atrial Mass and Cardiac Tamponade. [PDF]

J Brown Hosp Med
Kothari C, Kattamuri L, Ramesh P, Zalaquett Z, Collier P, Alencherry B, Nanjundappa A.   +6 more
europepmc   +1 more source

Characterization of the MIR23A Cluster in Diffuse Large B Cell Lymphoma [PDF]

, 2017
Natalie Veronika Freytag
openalex   +1 more source

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Journal of Clinical Oncology, 2015
J. Kochenderfer, M. Dudley, Sadik H. Kassim, R. Somerville, R. O. Carpenter, M. Stetler-Stevenson, J. Yang, G. Phan, M. Hughes, R. Sherry, M. Raffeld, Steven R. Feldman, Lily Lu, Yong F Li, L. Ngo, A. Goy, T. Feldman, D. Spaner, Michael L. Wang, Clara C. Chen, S. Kranick, A. Nath, Debbie-Ann N. Nathan, K. Morton, M. A. Toomey, S. Rosenberg   +25 more
semanticscholar   +1 more source

ATF6 and pS6K as prognostic biomarkers in newly diagnosed diffuse large B-cell lymphoma. [PDF]

Sci Rep
Su S, Wu L, Huang C, Wang L, Li W, Liu W, Liu L.   +6 more
europepmc   +1 more source

Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes

, 2019
Yangying Zhou, Zhijie Xu, Wei Lin, Yumei Duan, Can Lu, Wei Liu, Weiping Su, Yuanliang Yan, Huan Liu, Li Liu, Meizuo Zhong, Jianhua Zhou, Hong Zhu   +12 more
openalex   +1 more source

Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients

, 2023
Yan Qin, Xiaohui He, Xinrui Chen, Zucheng Xie, Jianliang Yang, Sheng Yang, Peng Liu, Shengyu Zhou, Changgong Zhang, Lin Gui, Yuankai Shi   +10 more
openalex   +1 more source

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study

British Journal of Haematology, EarlyView.
Summary A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102; <65 ...
Swetha Kambhampati Thiruvengadam, Leslie L. Popplewell, Alex F. Herrera, Matthew Mei, Liana Nikolaenko, Xiaofang Zuo, Shen Yin, Mingzhu Zhou, Yong Mun, Mei Wu, Michael C. Wei, Lihua E. Budde   +11 more
wiley   +1 more source

Bioinformatics Identification of SPAG5 as a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma. [PDF]

J Blood Med
Yan X, Liu L, Li J, Zhang H, Wang L, Liu L.   +5 more
europepmc   +1 more source

Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma

British Journal of Haematology, 2008
C. Lawrie, S. Gal, Heather M. Dunlop, Beena Pushkaran, A. Liggins, K. Pulford, A. Banham, F. Pezzella, J. Boultwood, J. Wainscoat, C. Hatton, A. Harris   +11 more
semanticscholar   +1 more source